Breast Cancer Proteomics and Molecular Heterogeneity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCancer Trials Ireland
About this trial
Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue
Patients receiving neoadjuvant treatment are also eligible (if applicable)
Patients have to be ≥ 18 years of age
Patients must be able to give informed consent
Disqualifiers
None
Trial population
All newly diagnosed breast cancer patients, recurrent and stage IV metastatic breast cancer patients.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
1,780 Participants
are grouped into 2 trial groupsGroup A: Primary Breast Cancer
Group B: Recurrent/Metastatic Breast Cancer
Trial outcomes
Primary outcomes
1
Investigation of proteins and their pathways in primary breast cancer
Investigation of proteins and their pathways in primary breast cancer, which are associated with patient outcome.
Time frame
10 yearsSecondary outcomes
1
Comparison of the molecular profile between primary and recurrent/metastatic lesions in breast cancer
Time frame
10 years2
Identification of novel molecular mechanisms of breast cancer recurrence
Identification of novel molecular mechanisms of breast cancer recurrence, therapy resistance and/or metastasis
Time frame
10 years3
Determination of novel potential molecular targets
Determination of novel potential molecular targets that can be used to develop future prevention and treatment advances in patients with breast cancer
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov